The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•21 April 2026•

1 min read

Cosmos Health Launches '18 Series' Nutraceutical Platform in the U.S. Market

Key Facts

1Cosmos Health launched the '18 Series' platform targeting a $7.8 billion addressable market in the U.S.

Cosmos Health Inc. (NASDAQ: COSM) has officially introduced its premium '18 Series' nutraceutical platform in the United States, targeting an addressable market valued at $7.8 billion. The new product line is built on patented ingredients and published clinical research, ensuring pharmaceutical-grade standards through exact clinical dosing. The company has debuted its first three products—Noor18, Liv18, and Cur18—as part of a broader roadmap to launch a total of 18 clinically validated supplements. This strategic move aims to capture market share by addressing consumer demand for transparency and science-backed wellness solutions. By entering this high-growth sector, Cosmos Health positions itself for potential long-term revenue expansion within the U.S. healthcare landscape. The launch underscores the company's commitment to diversifying its portfolio with high-barrier-to-entry products.